Aeglea BioTherapeutics Investor Presentation Deck
February 2022, 33 slides
  1. Aeglea BioTherapeutics
  2. Related Decks
  3. Investor Presentation Decks
patient on deficiency | Aeglea BioTherapeutics
forward looking statements disclosures | Aeglea BioTherapeutics
addressing metabolic imbalances to improve the lives of patients | Aeglea BioTherapeutics
agenda | Aeglea BioTherapeutics
overview of deficiency diagnosis and role of arginine northwestern medicine | Aeglea BioTherapeutics
deficiency | Aeglea BioTherapeutics
deficiency | Aeglea BioTherapeutics
diagnosis and management | Aeglea BioTherapeutics
case study clap medicine | Aeglea BioTherapeutics
patient medical history birth to genetics referral | Aeglea BioTherapeutics
patient medical history birth to genetics referral years tier enzymes | Aeglea BioTherapeutics
diagnosis | Aeglea BioTherapeutics
diagnostic methods and biochemistry labs ate glutamine | Aeglea BioTherapeutics
long term outcomes | Aeglea BioTherapeutics
long term outcomes continued see | Aeglea BioTherapeutics
summary and conclusions | Aeglea BioTherapeutics
is a debilitating metabolic disease that severely impairs patients quality of life | Aeglea BioTherapeutics
thank you | Aeglea BioTherapeutics
enzyme therapy approach to treating deficiency and review of clinical data a | Aeglea BioTherapeutics
deficiency | Aeglea BioTherapeutics
program overview | Aeglea BioTherapeutics
peace phase study design | Aeglea BioTherapeutics
measuring the functional impact of spasticity in | Aeglea BioTherapeutics
safety profile results from peace | Aeglea BioTherapeutics
primary met marked and sustained reduction in plasma arginine | Aeglea BioTherapeutics
normalization of plasma arginine levels in patients | Aeglea BioTherapeutics
peace mobility assessed by and | Aeglea BioTherapeutics
improvements in mobility measures sustained over time in phase and mean change from sown own sous am | Aeglea BioTherapeutics
summary of findings and future impact | Aeglea BioTherapeutics
thank you | Aeglea BioTherapeutics
patient advisor and steering committee member of the deficiency foundation | Aeglea BioTherapeutics
a | Aeglea BioTherapeutics
| Aeglea BioTherapeutics
See More
Aeglea BioTherapeutics
Investor Presentation Decks
Biotechnology Decks
Healthcare Decks
Explore Topics
Plasma
Medicine
Mobility
Recent decks by Aeglea BioTherapeutics
Investor Presentation
October 2023
Investor Presentation
October 2023
Investor Presentation
September 2023
Investor Presentation
July 2023
See all presentations by Aeglea BioTherapeutics (14 decks)
Related decks
AstraZeneca
Investor Conference
January 2024
Absci
Investor Conference
January 2023
AstraZeneca
Results
February 2021
AstraZeneca
Investor Day
September 2022
uBiome
Start Up
June 2017
Minerva
IPO
October 2021
Kymera
Investor Presentation
June 2023
Tivic Health Systems
Investor Presentation
October 2022
Recent decks by Aeglea BioTherapeutics
See all presentations (14 decks)
Investor Presentation
October 2023
Investor Presentation
October 2023
Investor Presentation
September 2023
Investor Presentation
July 2023
AstraZeneca
Investor Conference
January 2024
Absci
Investor Conference
January 2023
AstraZeneca
Results
February 2021
AstraZeneca
Investor Day
September 2022
uBiome
Start Up
June 2017
Minerva
IPO
October 2021
Kymera
Investor Presentation
June 2023
Tivic Health Systems
Investor Presentation
October 2022
Search Thousands of Presentations by World Leading Companies
Trending:
Addressable Market
Ecosystem
Beauty Market
WACC
NFT
Management Team
Investment Highlights

Stay in the loop

Join our mailing list to stay in the loop with updates and newest feature releases

Presentations

Start Up
IPO
SPAC
M&A
Investor Day
Results
ESG
Credit
Investment Banking

Explore

Presentation Collections
Slide Collections

Company

Blog
Contact us
© 2021-2023 Slidebook.io